GenSight Biologics Provides September 2026 Business Updates
Regulatory News:GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today provided business updates covering t…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.